ABSTRACT
Intercellular communication via gap junctions has an important role in controlling cell growth and in maintaining tissue homeostasis. Connexin 43 (Cx43; also known as GJA1) is the most abundantly expressed gap junction channel protein in humans and acts as a tumor suppressor in multiple tissue types. Cx43 is often dysregulated at the post-translational level during cancer development, resulting in loss of gap junctions. However, the molecular basis underlying the aberrant regulation of Cx43 in cancer cells has remained elusive. Here, we demonstrate that the oncogenic E3 ubiquitin ligase NEDD4 regulates the Cx43 protein level in HeLa cells, both under basal conditions and in response to protein kinase C activation. Furthermore, overexpression of NEDD4, but not a catalytically inactive form of NEDD4, was found to result in nearly complete loss of gap junctions and increased lysosomal degradation of Cx43 in both HeLa and C33A cervical carcinoma cells. Collectively, the data provide new insights into the molecular basis underlying the regulation of gap junction size and represent the first evidence that an oncogenic E3 ubiquitin ligase promotes loss of gap junctions and Cx43 degradation in human carcinoma cells.
Footnotes
Competing interests
The authors declare no competing or financial interests.
Author contributions
Conceptualization: M.Z.T., C.H.B., T.A.F., L.M.K., N.L.R., V.S., A.B., R.A.L., E.L.; Methodology: M.Z.T., C.H.B., T.A.F., L.M.K., N.L.R., P.W.E., Z.Y., V.S., A.B., E.L.; Validation: M.Z.T., C.H.B., T.A.F., L.M.K., N.L.R., P.W.E., Z.Y., V.S., A.B.; Formal analysis: M.Z.T., C.H.B., T.A.F., L.M.K., N.L.R., P.W.E., Z.Y., V.S., A.B., R.A.L., E.L.; Investigation: M.Z.T., C.H.B., T.A.F., L.M.K., N.L.R., Z.Y., V.S., A.B., E.L.; Resources: R.A.L., E.L.; Writing - original draft: M.Z.T., C.H.B., T.A.F., L.M.K, N.L.R., E.L.; Writing - review & editing: M.Z.T., C.H.B., T.A.F., L.M.K., N.L.R., P.W.E., V.S., A.B., R.A.L., E.L.; Visualization: M.Z.T., L.M.K., A.B., R.A.L., E.L.; Supervision: E.L.; Project administration: E.L.; Funding acquisition: R.A.L., E.L.
Funding
This work was supported by Kreftforeningen (Norwegian Cancer Society) (709125 to E.L.); Norges Forskningsråd (Research Council of Norway through its Centres of Excellence funding scheme) (project number 179571 to R.A.L, A.B., V.S., and E.L.), and Stiftelsen Kristian Gerhard Jebsen (to R.A.L.).
Supplementary information
Supplementary information available online at http://jcs.biologists.org/lookup/doi/10.1242/jcs.202408.supplemental
- Received February 13, 2017.
- Accepted July 12, 2017.
- © 2017. Published by The Company of Biologists Ltd